{
    "Trade/Device Name(s)": [
        "MIO Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Mio Labs Inc.",
    "510(k) Number": "K223722",
    "Predicate Device Reference 510(k) Number(s)": [
        "K173140"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "May 30, 2023",
    "Summary Letter Received Date": "June 2, 2023",
    "Submission Date": "May 25, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "MIO Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric detection",
        "Electrochemical biosensor"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip"
    ],
    "Document Summary": "FDA 510(k) summary for MIO Blood Glucose Monitoring System for quantitative glucose measurement using amperometric electrochemical biosensor technology",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in fresh capillary whole blood from the fingertip, for self-testing by persons with diabetes at home to monitor diabetes control effectiveness; not for neonatal use or diagnosis/screening of diabetes; single-user in vitro diagnostic use.",
    "fda_folder": "Clinical Chemistry"
}